There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kazia Therapeutics (KZIA), Atara Biotherapeutics (ATRA) and AbCellera Biologics (ABCL) with bullish sentiments.
Kazia Therapeutics (KZIA)
H.C. Wainwright analyst Sean Lee CFA initiated coverage with a Buy rating on Kazia Therapeutics today and set a price target of $17.00. The company’s shares closed last Monday at $8.98.
According to TipRanks.com, CFA is a 4-star analyst with an average return of 39.5% and a 73.3% success rate. CFA covers the Healthcare sector, focusing on stocks such as ThermoGenesis Holdings, CASI Pharmaceuticals, and Gritstone Oncology.
Kazia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $17.00.
See today’s analyst top recommended stocks >>
Atara Biotherapeutics (ATRA)
Canaccord Genuity analyst John Newman maintained a Buy rating on Atara Biotherapeutics yesterday and set a price target of $78.00. The company’s shares closed last Monday at $19.64.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 22.9% and a 45.5% success rate. Newman covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Allogene Therapeutics, and Aileron Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atara Biotherapeutics with a $37.86 average price target, implying a 92.8% upside from current levels. In a report released yesterday, Roth Capital also maintained a Buy rating on the stock with a $30.00 price target.
AbCellera Biologics (ABCL)
Berenberg Bank analyst Gal Munda maintained a Buy rating on AbCellera Biologics today and set a price target of $53.00. The company’s shares closed last Monday at $39.10, close to its 52-week low of $37.62.
According to TipRanks.com, Munda is ranked #592 out of 7185 analysts.
AbCellera Biologics has an analyst consensus of Moderate Buy, with a price target consensus of $50.50, representing a 26.3% upside. In a report released today, BMO Capital also initiated coverage with a Buy rating on the stock with a $48.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
